Review Article

Molecular Mechanisms Linking Oxidative Stress and Diabetes Mellitus

Habib Yaribeygi 1, Thozhukat Sathyapalan, 2 Stephen L. Atkin 3, and Amirhossein Sahebkar 4,5,6

1 Research Center of Physiology, Semnan University of Medical Sciences, Semnan, Iran
2 Department of Academic Diabetes, Endocrinology and Metabolism, Hull York Medical School, University of Hull, Hull HU3 2JZ, UK
3 Weill Cornell Medicine Qatar, Doha, Qatar
4 Halal Research Center of IRI, FDA, Tehran, Iran
5 Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
6 Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Correspondence should be addressed to Habib Yaribeygi; habib.yari@yahoo.com and Amirhossein Sahebkar; amir_saheb2000@yahoo.com

Received 2 November 2019; Revised 7 December 2019; Accepted 4 February 2020; Published 9 March 2020

Academic Editor: Carlo G. Tocchetti

Copyright © 2020 Habib Yaribeygi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Type 2 diabetes mellitus (T2DM) is the most prevalent metabolic disorder characterized by chronic hyperglycemia and an inadequate response to circulatory insulin by peripheral tissues resulting in insulin resistance. Insulin resistance has a complex pathophysiology, and it is contributed to by multiple factors including oxidative stress. Oxidative stress refers to an imbalance between free radical production and the antioxidant defense systems leading to a reduction of peripheral insulin sensitivity and contributing to the development of T2DM via several molecular mechanisms. In this review, we present the molecular mechanisms by which the oxidative milieu contributes to the pathophysiology of insulin resistance and diabetes mellitus.

1. Introduction

The prevalence of diabetes mellitus (DM) is growing exponentially worldwide at an epidemic proportion [1]. This chronic disorder has a negative effect on most metabolic pathways and contributes to the pathophysiology of diabetes complications of [2, 3]. Diabetic complications result in considerable morbidity and mortality leading to major healthcare delivery costs [4]. Although there are several studies to elucidate the molecular mechanisms underlying the development of diabetes complications [5–8], their precise pathophysiology is not completely understood [8]. One of the major mechanisms for the development of diabetes complications is through oxidative stress [8]. Oxidative stress develops when the rate of free radical generation exceeds the antioxidant defense systems resulting in the toxic effects of free radicals [9, 10]. Free radical species are important physiological components in biological homeostasis [11, 12], but when their production increases excessively and greater than the body’s antioxidant capacity, then oxidative stress results [12]. Oxidative stress is a major upstream event for diabetes complications as well as insulin resistance development [12–14], inducing pathophysiologic molecular mechanisms and initiating a cascade of deleterious pathways leading to insulin resistance and DM [8, 15]. In this review, we discuss the potential roles of oxidative stress in the development of insulin resistance and DM.

2. Classification of Diabetes Mellitus

There are different types of DM, but the common subtypes are type 1 DM (T1DM) and type 2 diabetes (T2DM) [16]. T1DM accounts for about 5-10% of all patients with DM which results from beta-cell dysfunction, reduction in insulin release, and lower levels of circulatory insulin [16]. T2DM is the most prevalent type of DM which accounts for about 90-
95% of patients with diabetes and is mainly linked to inadequate response to insulin (reduced insulin sensitivity) and insulin resistance in peripheral tissues [16]. Gestational diabetes is another subtype of DM which occurs in pregnant women due to hormonal variations during pregnancy [17]. The other forms of DM are maturity-onset diabetes of the young which is a genetic form of diabetes, latent autoimmune diabetes in adults, and secondary diabetes resulting from other pathologies such as pancreatitis or secondary to the use of medications such as corticosteroids [18, 19].

3. Oxidative Stress and Antioxidant Defense System in β Cells

Free radicals are active biomolecules which are physiologically generated during metabolic pathways and/or by immune cells [20]. Free radicals have physiological roles in many molecular pathways including those of cellular signaling, synaptic plasticity, memory formation, defense against invader pathogens, cell-cell interactions, cell growth, autophagy, apoptotic processes, and aging [21–24]. When free radical generation increases above the physiological range, it overcomes the antioxidant mechanisms of cells and results in oxidative stress [23, 24]. Most biologic cells have an intrinsic defense mechanism involving various enzymes such as superoxide dismutase (SOD), catalase (CAT), and glutathione (GLT), which protect cells against free radical attack [25].

Free radicals are active derivatives of either the oxygen molecule such as reactive oxygen species (ROS: hydroperoxy, superoxide, hydrogen peroxide, and hydroxyl radicals) and nitrogen molecules such as the reactive nitrogen species (RNS) peroxynitrite [23]. Some heavy metal derivatives such as iron (ferric) and copper have free radical properties [26]. These hyperactive elements have unpaired electrons in their outer layer of molecules and thereby can bind with other biomolecules and modify them [20, 27]. They can oxidize proteins, lipids, and nucleic acids and produce toxic byproducts leading to tissue dysfunction [27, 28]. Also, they alter the structures of biologic molecules and even break them [28]. DNA breakage is a known effect of oxidative stress, which affects the expression of most genes and cell survival [23]. Free radicals not only have direct deleterious effects, but also can indirectly damage cells by activating a variety of stress-sensitive intracellular signaling pathways such as Nf-κB (nuclear factor kappa b), p38 MAPK (p38 mitogen-activated protein kinases), JNK/SAPK (stress-activated protein kinase/c-Jun NH2-terminal kinase), hexosamine pathways, PKC (protein kinase C), AGE/RAGE (advanced glycation end product/receptor for AGE) interactions, and sorbitol synthesis [29]. The various biomarkers for oxidative stress in patients with diabetes include malondialdehyde (MDA), total cholesterol, and reactive hydroperoxides (ROOH) [30]. Oxidative stress has pivotal roles in the pathophysiology of various complications of diabetes through lipid peroxidation, DNA damage, and mitochondrial dysfunction [13, 23, 31, 32]. It is also closely involved in many other pathological conditions as well as age-related disorders such as cardiovascular diseases, chronic obstructive pulmonary disease, chronic kidney disease, neurodegenerative diseases, and cancer [33]. Aging and its related disorders are identified as the progressive loss of tissue function through differing mechanisms including elevated free radical species [33]. Many scientists believe that the oxidative stress theory is the major cause of aging and age-related complications [33]. Hence, maintaining the normal state of redox biology is of importance to prevent oxidative stress-induced complications as well as insulin resistance [34].

4. Normal Insulin Signaling Pathways and Insulin Resistance

Insulin resistance is the main underlying pathology in T2DM in which cells are unable to respond to insulin effectively and thereby have a suboptimal uptake of glucose [8, 35]. Normal insulin signal transduction (IST) has complex sequential steps involving different enzymes and mediators, which results in facilitated glucose entry into the adipocytes, muscles, and myocardial cells via GLUT-4 (glucose transporter-4) transporters [8, 34]. The IST is initiated by the binding of insulin to the α chain of its specific receptors known as insulin receptors (IRs), which are members of the transmembrane tyrosine kinases composed of α and β chains and activated by insulin as well as by IGF-1 (insulin-like growth factor-1) and IGF-2 [36]. This binding induces structural changes in the β chain by autophosphorylation in tyrosine residues followed by downstream events such as recruitment of different adaptor proteins, i.e., insulin receptor substrates (IRs), Shc (SHC-transforming) protein, and APS protein (adapter protein with a PH and SH2 domain) [37, 38]. These processes provide an appropriate binding site for the IRS-1 (insulin receptor substrate-1) [38]. Several types of insulin-dependent kinases such as ERK1/2 (extracellular signal-regulated kinase 1/2), atypical PKC (protein kinase C), S6K1 (ribosomal protein S6 kinase beta-1), SIK2 (serine/threonine-protein kinase 2), Akt (protein kinase B), mTOR (mammalian target of rapamycin), and ROCK1 (rho-associated protein kinase 1) and other types of kinases such as AMPK (AMP-activated protein kinase) and GSK-3 (glycogen synthase kinase 3) can phosphorylate IRSs and activate them [38, 39]. Activated IRS-1 binds to PI3K (phosphoinositide 3-kinase) and activates it which, in turn, catalyzes the conversion of PIP2 (phosphatidylinositol 4,5-bisphosphate) to PIP3 (phosphatidylinositol 3,4,5-trisphosphate) [40]. PIP3 is itself a potent activator for Akt, which in turn facilitates glucose entering into the cells by localization of GLUT-4 and by inhibiting glycogen synthase kinase leading to more glycogen synthesis [40, 41]. Any disturbance in these steps can potentially impair normal IST thereby inducing insulin resistance and DM [34].

5. Possible Links between Oxidative Stress and Insulin Resistance

As described before, oxidative stress can impair IST and increase the risk of insulin resistance and DM [26, 34]. It must be noted that oxidative stress and DM have complex interactions whereby both intensify each other [42, 43]. In the following sections, we review the possible molecular
pathways by which free radicals impair normal glucose homeostasis contributing to the development of DM.

5.1. **β-Cell Dysfunction/Insulin Production and Secretion.** A healthy and functional mass of pancreatic beta cells is necessary for normal glucose homeostasis, and DM is accompanied with varying levels of beta-cell dysfunction [44, 45]. A progressive loss of beta-cell mass and function is a major contributor for developing DM [46]. In these conditions, glucose-induced insulin secretion from beta cells becomes deregulated and declines, and therefore, postprandial glucose becomes elevated above the normal [47]. In this process, an initial defect in early or first-phase insulin release occurs, which is then followed by a decreasing maximal capacity of glucose to stimulate postprandial insulin release followed by complete beta-cell failure [46]. Beta-cell dysfunction results from many pathogenic pathways as well as oxidative stress [46, 48].

Mitochondrial respiratory chains (MRC) and NADPH (nicotinamide adenine dinucleotide phosphate) oxidase or NOX enzyme activity are the major sources of free radicals in the pancreatic beta cells [15, 49–51]. Superoxide anion (O$_2^-$) is the main form of free radical species produced by MRC and NOX enzymes in the beta cells [52]. The phagocytic and immune cells can also produce free radicals that can attack the beta cells [53]. Chronic hyperglycemia induces free radical generation in islets through several molecular pathways such as an increase of cytosolic calcium and protein kinase activation [50, 54]. Since beta cells have a low capacity of the antioxidant defense system, oxidative stress in beta cells is prevalent in DM and plays an important role for the loss of their function in both T1DM and T2DM [45, 48, 55].

Oxidative stress impairs beta-cell function via several molecular mechanisms [48, 55, 56] [57–62]. It markedly reduces insulin production, impairs inclusion of proinsulin vesicles into the plasma membrane, and reduces their exocytosis in response to glucose into the circulation [48, 55, 56]. It can also induce apoptotic processes in the pancreatic cells leading to death and loss of beta cells [48, 55, 56]. A series of proapoptotic agents are highly sensitive to oxidative stress and can activate the apoptotic process in the pancreatic cells [63–65]. Moreover, an overload of free radical species has a negative effect on metabolic pathways in the beta cells and impairs K$_{ATP}$ channels leading to lower insulin secretion [48, 61] (Figure 1). The free radicals impair K$_{ATP}$ channels by binding to their SH residues [57–59], confirmed by studies demonstrating that genetic knockout models of K$_{ATP}$ channels in beta cells resulted in their protection against oxidative stress [61].

Higher concentrations of free radicals inhibit the nuclear transcription factors involved in insulin gene expression as Pdx-1 (insulin promoter factor 1) and MafA (a transcription factor) thereby reducing insulin production at the DNA level [60]. Wang and Wang in 2017 reported that oxidative stress induced molecular pathways such as NF-xb, JNK/SAPK, p38 MAPK, and hexosamine pathways [62]. These stress-activated signaling pathways have a pivotal role in beta-cell dysfunction [62]. Free radicals can also activate TLRs (toll-like receptors) that in turn impair beta-cell function [66, 67]. Oxidative stress-induced mitochondrial dysfunction in the beta cell is another possible molecular mechanism between oxidative damage and beta-cell dysfunction [48].

Although free radicals have a physiological role in beta-cell proliferation, excess of free radicals will disturb the beta-cell neogenesis [62, 68, 69]. Miceli and coworkers in 2018 found that oxidative stress markedly disturbed beta-cell function in an in vitro experiment [70]. They imposed oxidative stress on rat INS-1E and mouse MIN6 beta-cell lines by exposure to 200 μM hydrogen peroxide (H$_2$O$_2$) and found that glucose-stimulated insulin secretion was significantly reduced in these cells [70]. Moreover, this event was completely reversed by using carnosine as an antioxidant [70]. Oxidative stress decreases the proliferation and differentiation of beta cells by complex interactions with different factors such as Pdx-1, Nkx6.1, Ngn.3, FOXO, and MafA [62, 71, 72]. These transcriptional mediators are highly sensitive to the redox imbalance, and exposure to higher levels of free radicals negatively modulates the proliferation of the beta cell [71, 72]. Therefore, oxidative stress-induced beta-cell dysfunction is a major pathway where novel therapeutic

![Figure 1: Possible molecular mechanisms between oxidative stress and beta-cell dysfunction leading to diabetes mellitus.](image-url)
interventions could be targeted in patients with DM. We suggest that pharmacologic agents protecting islets against oxidative damage can provide a new age of promising therapeutic targets to promote beta-cell function leading to an improvement of glucose homeostasis.

5.2. GLUT-4 Expression and/or Localization. As noted above, GLUT-4 regulates glucose entering into the insulin-dependent cells such as adipocytes and myocytes, and therefore, a normal physiological profile of GLUT-4 expression and/or localization is necessary for maintaining insulin sensitivity in these tissues [15, 73]. Any factor which reduces GLUT-4 expression has a marked effect on insulin sensitivity [73, 74] as there is a reduction of glucose entering into the target cells that translates into lower insulin sensitivity in these tissues [75]. Clinical studies show that the GLUT-4 expression and/or localization is lower in patients with insulin resistance and T2DM [74, 76, 77]. This pathophysiologic state is promoted by oxidative stress by the mechanisms noted below [78, 79].

Oxidative stress can reduce GLUT-4 content by negatively effecting its gene expression by impairing the binding of nuclear factor to the insulin responsive element of the GLUT-4 promoter in 3T3-L1 adipocytes [80]. Pessler et al. in 2001 exposed 3T3-L1 adipocytes to micro molar H2O2 GLUT-4 promoter in 3T3-L1 adipocytes [80]. Pessler et al. of nuclear factor to the insulin responsive element of the GLUT-4 expression and/or localization is lower in patients with insulin resistance and T2DM [74, 76, 77]. This pathophysiologic state is promoted by oxidative stress by the mechanisms noted below [78, 79].

5.3. Insulin Signaling Pathways. Any defects in the insulin signaling pathways could potentially contribute to the development of insulin resistance and DM [89, 90]. Modulation of IST has been introduced as a novel therapeutic target for promoting insulin sensitivity [90]. Oxidative stress can impair normal IST at different levels including IRS, IRS-1 and IRS-2; PI3K enzyme; and Akt signaling pathways [91–96]. Balbaa and colleagues in 2017 induced T2DM-induced oxidative stress and then determined IST elements in the brain of diabetic rats [97]. They found that oxidative stress markedly reduced IST element expression as p-IRS, p-AKT, and GSK-3β in brain tissues and Nigella sativa oil reversed these events and normalized insulin signaling [97].

Oxidative stress induces IRS-1 and IRS-2 serine phosphorylation, which in turn results in a disturbed IST [91, 92]. Free radicals can induce serine phosphorylation of IRS-1 (at the site of 307) and suppress the normal IST via activation of JNK/SAPK signaling pathways [95]. Moreover, they can inhibit normal IST by p38 MAPK-dependent molecular mechanisms, and inhibition of this molecular pathway restored the normal IST in vitro and in a diabetic animal model [93, 94]. Hyperglycemia-induced oxidative stress activates different stress-sensitive serine/threonine (Ser/Thr) kinases such as IKK-β which in turn phosphorylate multiple targets such as the IRSs, IRS-1 and IRS-2, leading to unfavorable downstream effects including lower PI3K activation and insulin resistance [29]. It has been shown that salicylates, an inhibitor of IKK-β, restored the normal IST in oxidative stress in vitro [98, 99]. Other types of serine/threonine kinases such as Akt (or PKB), GSK-3, AMPK, and mTOR are also very sensitive to oxidative stress and may impair insulin signaling [100–102].

Oxidative stress can also result in impairment of IST via downregulation of proteins involved in the normal IST [97]. The main elements of IST such as Akt, IRS, IRS-1, and GSK-3 are under the influence of free radicals that are downregulated by the oxidative stress thereby impairing insulin sensitivity leading to insulin resistance and DM [97]. Hence, impairment of the normal IST is another important link between oxidative stress and insulin resistance [91–96, 100–102] (Figure 2).

5.4. Inflammatory Processes. The inflammatory response is one of the main underlying molecular mechanisms involved in the pathophysiology of insulin resistance, DM, and its related complications [53, 103, 104]. There is growing evidence that low-grade chronic inflammation is involved in the pathophysiology of insulin resistance and DM [104–110]. These deleterious processes can also initiate other pathophysiologic mechanisms of DM such as impairment of IST and beta-cell dysfunction [53, 107]. The interaction between inflammatory responses and DM is complex and not fully elucidated [111]. Cytokines can induce Janus kinase pathways (JNKs) which in turn stimulate IRS-1 serine phosphorylation leading to an impairment in IST [112]. These effects were also reported for other inflammatory mediators such as TNF-α and NF-κb which can modulate IRS-1 serine phosphorylation at various sites and thereby impair normal IST [112–114]. Higher levels of monocytes and macrophage activity and circulatory mediators such as CX3CL1 (fractalkine), CRP
(C-reactive protein), TNF-α (tumor necrosis factor-alpha), IL-6 (interleukin-) 6, IL-1β, IL-18, MCP-1 (monocyte chemoattractant protein-1), resistin, PAI-1 (plasminogen activator inhibitor-1), E-selectin, and IFN-γ (interferon-gamma) have been detected in patients with diabetes [104, 106–110]. Therefore, ameliorating these inflammatory processes may be a therapeutic option for the management of diabetes [105, 115, 116].

Many ongoing and/or completed clinical studies have reported the importance of anti-inflammatory agents in glucose homeostasis [117]. For example, Goldfine and coworkers in 2010 evaluated the glucose-lowering effects of salsalate (a prodrug of salicylate) and reported that it was effective in reducing HbA1c and fasting plasma glucose in T2DM patients [117]. Clinical trials that have been undertaken with agents to reduce oxidative stress and their outcomes are shown in Table 1.

Oxidative stress is an upstream event for inflammation as it induces the activation of monocytes and macrophages as well as promotes inflammatory responses involved in insulin resistance and DM [115, 123, 124]. It also upregulates the expression of procytokines and thereby increases the inflammatory mediators at both the mRNA and protein levels [100, 125]. Hence, free radical-induced inflammation is another possible link between oxidative stress and insulin resistance [111].

5.5. Systemic Mitochondrial Dysfunction. Mitochondria are double-membrane cellular organelles that have important roles in energy production, calcium storage, fatty acid production, heat production, and cell survival and act as part of cellular signaling pathways [126, 127]. It has been shown that mitochondrial dysfunction is involved in the pathophysiology of insulin resistance and DM; however, the underlying mechanisms remain unclear [128]. Oxidative stress is a key player in most cases of mitochondrial dysfunction [129], impairing mitochondrial function via altering the normal function of the MRC, reducing the respiratory capacity of mitochondria, increasing the proton leak in MRC, altering the potential difference across the inner mitochondrial membrane, and reducing the integrity of mitochondrial membranes [130–132]. These processes may occur locally in the pancreatic islets and/or systemically in adipocytes and muscular tissues [133].

The normal process of glucose uptake via GLUT-4 is closely dependent on the physiological functioning of healthy mitochondria [134] that produce the energy needed for glucose uptake in peripheral tissues [134]. Accordingly, mitochondrial dysfunction markedly reduces the cellular ATP production capacity and impairs the insulin-induced glucose uptake in adipocytes and muscle cells [100]. In these conditions, cells are unable to uptake the circulating glucose in response to insulin resulting in insulin resistance [100, 133, 135]. In addition, oxidative stress can impair normal mitochondrial function by increasing mitochondrial fatty acid oxidation and DAG (diacylglycerol) production, which in turn activates more serine/threonine kinases leading to impaired IST [100]. Hence, oxidative stress-dependent mitochondrial dysfunction is another molecular mechanism by which free radicals result in insulin resistance [100, 133, 135]. It must be noted that oxidative stress and mitochondrial dysfunction have dual interactions in which both can potentiate each other [136].

6. Animal Studies and the Effect of Reducing Oxidative Stress

There is an increasing body of evidence from animal studies confirming oxidative stress-induced insulin resistance and the improvement in IST and glucose homeostasis by using antioxidative agents [93, 94, 132]. Jolivalt and coworkers in 2008 found that high levels of free radical species in brain tissue impaired IST expression and induced insulin resistance in diabetic mice [89]. Agil et al. in 2015 demonstrated that antioxidative properties of melatonin ameliorated insulin resistance by improvement in mitochondrial function in diabetic rats [132]. In addition, Balbaa et al. in 2017 reported that oxidative stress downregulated IST elements in the brain of diabetic animals and demonstrated that it could be reversed by antioxidative agents [97]. Moreover, Zhang and colleagues in 2017 found that myricitrin (a flavonoid) improved insulin sensitivity and glucose homeostasis by attenuating the inflammatory responses and oxidative damage in diabetic mice [123]. Hininger-Favier and coworkers in 2009 evaluated the antioxidative effects of green tea on insulin sensitivity and found that it markedly improved insulin resistance in diabetic rats [137]. Bagul et al. in 2012 reported that antioxidative properties of resveratrol reversed oxidative stress-dependent insulin resistance in diabetic rats [138]. Recently, Sahin et al. in 2019 reported that a phytochemical compound of allyl isothiocyanate significantly increased insulin sensitivity by lowering oxidative stress.

\[ \frac{\text{IRS-1 and IRS-2 serine phosphorylation}}{\text{Induces IKK-β activity}} \] \( \downarrow \)

\[ \text{Modulates Akt (or PKB), GSK-3, AMPK and mTOR activities} \]

\[ \text{Downregulates IST elements} \]

\[ \text{Induces p38 MAPK pathway} \]

\[ \text{Insulin signaling pathways} \]

\[ \text{Insulin resistance} \]
Table 1: Clinical trials undertaken with anti-inflammatory agents.

| Study population                  | Study design                                           | Treatment       | Dose                        | Results                                                                 | Ref.  |
|-----------------------------------|--------------------------------------------------------|-----------------|-----------------------------|-------------------------------------------------------------------------|-------|
| 81 patients with T2DM             | Randomized double-blind placebo-controlled trial       | Salsalate       | 3.0, 3.5, or 4.0 g/d for 14 weeks | Reduced the HbA1c and FBG                                                | [117] |
| 20 obese nondiabetic adults       | Randomized double-blind placebo-controlled trial       | Salsalate       | 4.0 g/day for 4 weeks       | Declined FBG, HbA1c and C-peptide and increased adiponectin             | [118] |
| 70 patients with T2DM             | Randomized double-blind placebo-controlled trial       | Anakinra, a     | 13 weeks                    | Alleviated inflammatory markers and improved glucose control even after  | [119] |
|                                   |                                                        | recombinant     |                             | treatment withdrawal                                                     |       |
|                                   |                                                        | human IL-1R     |                             |                                                                         |       |
| 15 patients with T2DM             | Open-label trial\(^a\) and randomized double-blind    | Salsalate       | 3 and 4.5 g/d for 2 weeks   | Improved glucose control, circulating free fatty acid, and adiponectin   | [118] |
|                                   | placebo-controlled trial\(^b\)                        |                 |                             |                                                                         |       |
| 286 patients with T2DM            | Randomized double-blind placebo-controlled trial       | Salsalate       | 3.5 g/d for 48 weeks        | Reduced mean HbA1c                                                       | [120] |
| 257 patients with T2DM            | Randomized double-blind placebo-controlled trial       | Salsalate       | 3.5 g/d for 30 months       | Reduced inflammatory markers and FBG                                     | [121] |
| 7,000 patients with MI and insulin resistance | Randomized double-blind placebo-controlled trial | Methotrexate    | 15-20 mg/wk for 3-5 years   | Reduced inflammatory markers and HbA1c                                   | [122] |

Anakinra: a recombinant human IL-1 receptor; FBG: fasting blood glucose; HbA1c: glycated hemoglobin; MI: myocardial infarction. \(^a^Two studies with open-label design at doses of 3 and 4.5 g/day. \(^b^One study with a randomized double-blind placebo-controlled design.
and inflammatory responses in diabetic rats [139]. Additionally, Abdulmalek and Balbaa in 2019 examined the potential of selenium and found that it promoted insulin sensitivity by ameliorating inflammation and oxidative stress in diabetic rats [140]. These data complement the results of basic studies suggesting oxidative stress induces insulin resistance and DM [97, 123, 132, 137, 139, 140].

Whilst relatively few, there is clinical evidence supporting the animal studies [141]. Udupa et al. conducted a clinical trial on T2DM patients and found that antioxidant agents of omega 3 fatty acids, α-tocopherol, and α-lipoic acids improved insulin sensitivity in these patients [141]. Manning and coworkers in 2004 reported that high dose vitamin E, a potent antioxidant, transiently improved insulin sensitivity in obese subjects [142]. Ganjifrockwala et al. in 2017 reported that an antioxidant-rich diet decreased oxidative markers accompanied with improved insulin sensitivity in T2DM patients [143]. More recently, van der Schaft and coworkers reported in a large epidemiological study involving 5796 participants that consumption of a diet rich in antioxidants was associated with restoring insulin sensitivity in T2DM patients [144]. These findings suggest that antioxidative agents might effectively improve IST in humans.

### 7. Current Knowledge and Future Perspective

Oxidative stress has a pivotal role in the pathophysiology of insulin resistance and DM, as well as many other complications of diabetes [100, 145]. An increasing number of in vivo studies suggest that higher amounts of free radicals markedly impair normal IST and glucose homeostasis in several ways [100]. Although we have outlined the state-of-the-art knowledge in this field and summarized it into five molecular mechanisms, more cellular pathways may be discovered in the future. More clinical studies using promising antioxidative agents are required to develop new...
preventive protocols for subjects who are at high risk of insulin resistance, i.e., obese subjects and their place in current therapeutics need to be determined. Antioxidants may play therapeutic roles in reversing insulin resistance in metabolic disorders such as DM, nonalcoholic fatty liver disease, and metabolic syndrome. In addition, a number of herbal-based agents (i.e., crocin, curcumin, cinnamon, and garlic) with confirmed antioxidative properties have potential value in the future [13, 146].

8. Conclusion

Oxidative stress has key roles in the pathophysiology of insulin resistance and DM (Figure 3). It can reduce peripheral insulin sensitivity via at least five major molecular mechanisms through β-cell dysfunction, inflammatory responses, GLUT-4 downregulation and/or localization, mitochondrial dysfunction, and impairment of the normal insulin signaling pathways (Table 2). We have described the oxidative milieu imposed by each of these pathways via several molecular mechanisms. Oxidative stress can impair normal IST by negatively modulating the IST elements such as IRS-1 and IRS-2, IKK-β activity, Akt, GSK-3, AMPK, and mTOR signaling pathways and p38 MAPK-dependent molecular mechanisms. It can also result in beta-cell dysfunction via induction of apoptotic events, impairing KATP channels, inhibiting transcription factors involved in β-cell neogenesis such as Pdx-1 and MafA, and inducing mitochondrial dysfunction in beta cells leading to lower insulin production/release. Oxidative stress reduces GLUT-4 expression and/or localization by suppressing transcriptional factors such as PPAR-γ, CEB/Ps, nuclear factor-1, p85, HIF-1α, MEF2, and Nf-kb, as well as various micro RNAs involved in the GLUT-4 expression. Similarly, oxidative stress induces inflammatory responses and beta-cell dysfunction leading to a lower rate of insulin sensitivity in peripheral tissues.

Conflicts of Interest

All authors declare that they have no conflict of interest in this study.

Acknowledgments

The authors are thankful to the Research Center of Physiology, Semnan University of Medical Sciences, Iran for providing technical support.

References

[1] E. J. Mayer-Davis, J. M. Lawrence, D. Dabelea et al., “Incidence trends of type 1 and type 2 diabetes among youths, 2002–2012,” The New England Journal of Medicine, vol. 376, no. 15, pp. 1419–1429, 2017.
[2] H. W. Baynest, “Classification, pathophysiology, diagnosis and management of diabetes mellitus,” Journal of Diabetes & Metabolism, vol. 6, no. 5, pp. 1–9, 2015.
[3] J. M. Forbes and M. E. Cooper, “Mechanisms of diabetic complications,” Physiological Reviews, vol. 93, no. 1, pp. 137–188, 2013.
[4] C. Bommer, E. Heesemann, V. Sagalova et al., “The global economic burden of diabetes in adults aged 20–79 years: a cost-of-illness study,” The Lancet Diabetes & Endocrinology, vol. 5, no. 6, pp. 423–430, 2017.
[5] F. Zaccardi, D. R. Webb, T. Yates, and M. J. Davies, “Pathophysiology of type 1 and type 2 diabetes mellitus: a 90-year perspective,” Postgraduate Medical Journal, vol. 92, no. 1084, pp. 63–69, 2016.
[6] S. E. Kahn, M. E. Cooper, and S. Del Prato, “Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future,” The Lancet, vol. 383, no. 9922, pp. 1068–1083, 2014.
[7] H. Yaribeygi, N. Katsiki, B. Behnam, H. Iranpanah, and A. Sahebkar, “MicroRNAs and type 2 diabetes mellitus: molecular mechanisms and the effect of antidiabetic drug treatment,” Metabolism, vol. 87, pp. 48–55, 2018.
[8] H. Yaribeygi, F. R. Farrokhhi, A. E. Butler, and A. Sahebkar, “Insulin resistance: review of the underlying molecular mechanisms,” Journal of Cellular Physiology, vol. 234, no. 6, pp. 8152–8161, 2019.
[9] H. Yaribeygi, F. R. Farrokhhi, R. Rezaee, and A. Sahebkar, “Oxidative stress induces renal failure: a review of possible molecular pathways,” Journal of Cellular Biochemistry, vol. 119, no. 4, pp. 2990–2998, 2018.
[10] H. Yaribeygi, S. L. Atkin, and A. Sahebkar, “Mitochondrial dysfunction in diabetes and the regulatory roles of antidiabetic agents on the mitochondrial function,” Journal of Cellular Physiology, vol. 234, no. 6, pp. 8402–8410, 2019.
[11] H. Yaribeygi, S. L. Atkin, A. E. Butler, and A. Sahebkar, “Sodium–glucose cotransporter inhibitors and oxidative stress: an update,” Journal of Cellular Physiology, vol. 234, no. 4, pp. 3231–3237, 2019.
[12] H. Yaribeygi, A. E. Butler, G. E. Barreto, and A. Sahebkar, “Antioxidative potential of antidiabetic agents: a possible protective mechanism against vascular complications in diabetic patients,” Journal of Cellular Physiology, vol. 234, no. 3, pp. 2436–2446, 2019.
[13] H. Yaribeygi, M. T. Mohammadi, and A. Sahebkar, “Crocin potentiates antioxidant defense system and improves oxidative damage in liver tissue in diabetic rats,” Biomedicine & Pharmacotherapy, vol. 98, pp. 333–337, 2018.
[14] H. Yaribeygi, M. T. Mohammadi, and A. Sahebkar, “PPAR-α agonist improves hyperglycemia-induced oxidative stress in pancreatic cells by potentiating antioxidant defense system,” Drug Research, vol. 68, no. 6, pp. 355–360, 2018.
[15] S. Hurrle and W. H. Hsu, “The etiology of oxidative stress in insulin resistance,” Biomedical Journal, vol. 40, no. 5, pp. 257–262, 2017.
[16] American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 37, Supplement 1, pp. S81–S90, 2014.
[17] J. de Faria Maraschin, “Classification of diabetes,” in Diabetes. Advances in Experimental Medicine and Biology, vol 771, S. I. Ahmad, Ed., pp. 12–19, Springer, New York, NY, USA, 2013.
[18] K. S. O’Neal, J. L. Johnson, and R. L. Panak, “Recognizing and appropriately treating latent autoimmune diabetes in adults,” Diabetes Spectrum, vol. 29, no. 4, pp. 249–252, 2016.
[19] American Diabetes Association, “Diagnosis and classification of diabetes mellitus,” Diabetes Care, vol. 33, Supplement 1, pp. S62–S69, 2010.
Oxidative Medicine and Cellular Longevity

[20] D. Stavness, I. Bosque, and C. R. Stephenson, "Free radical chemistry enabled by visible light-induced electron transfer," *Accounts of Chemical Research*, vol. 49, no. 10, pp. 2295–2306, 2016.

[21] L. Bokkon, "Recognition of functional roles of free radicals," *Current Neuropharmacology*, vol. 10, no. 4, p. 287, 2012.

[22] D. M. Brown, K. Donaldson, P. J. Borm et al., "Calcium and ROS-mediated activation of transcription factors and TNF-a cytokine gene expression in macrophages exposed to ultra-fine particles," *American Journal of Physiology-Lung Cellular and Molecular Physiology*, vol. 286, no. 2, pp. L344–L353, 2004.

[23] B. Halliwell and J. M. Gutteridge, *Free Radicals in Biology and Medicine*, Oxford University Press, USA, 2015.

[24] P. R. Angelova and A. Y. Abramov, "Role of mitochondrial ROS in the brain: from physiology to neurodegeneration," *FEBS Letters*, vol. 592, no. 5, pp. 692–702, 2018.

[25] A. C. Maritim, R. A. Sanders, and J. B. Watkins, "Diabetes, oxidative stress, and antioxidants: a review," *Journal of Biochemical and Molecular Toxicology*, vol. 17, no. 1, pp. 24–38, 2003.

[26] S. Tangvarasittichai, "Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus," *World Journal of Diabetes*, vol. 6, no. 3, pp. 456–480, 2015.

[27] R. Radi, A. Denicola, B. Morgan, and J. Zielonka, "Foreword to the free radical biology and medicine special issue on current fluorescence and chemiluminescence approaches in free radical and redox biology," *Free Radical Biology & Medicine*, vol. 128, pp. 1-2, 2018.

[28] H. Sies, C. Berndt, and D. P. Jones, "Oxidative stress," *Annual Review of Biochemistry*, vol. 86, pp. 715–748, 2017.

[29] J. L. Evans, I. D. Goldfine, B. A. Maddux, and G. M. Grodsky, "Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction?", *Diabetes*, vol. 52, no. 1, pp. 1–8, 2003.

[30] P. Rösen, P. P. Nawroth, G. King, W. Möller, H. J. Tritschler, and L. Packer, "The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a congress series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society," *Diabetes/Metabolism Research and Reviews*, vol. 17, no. 3, pp. 189–212, 2001.

[31] H. Yaribeygi, F. Lhaf, T. Sathyapalan, and A. Sahebkar, "Effects of novel antidiabetes agents on apoptotic processes in diabetes and malignancy: implications for lowering tissue damage," *Life Sciences*, vol. 231, article 116538, 2019.

[32] H. Yaribeygi, N. Faghihi, M. T. Mohammadzadeh, and A. Sahebkar, "Effects of atorvastatin on myocardial oxidative and nitrosative stress in diabetic rats," *Comparative Clinical Pathology*, vol. 27, no. 3, pp. 691–697, 2018.

[33] I. Liguori, G. Russo, F. Curcio et al., "Oxidative stress, aging, and diseases," *Clinical Interventions in Aging*, vol. 13, pp. 757–772, 2018.

[34] V. T. Samuel and G. I. Shulman, "The pathogenesis of insulin resistance: integrating signaling pathways and substrate flux," *The Journal of Clinical Investigation*, vol. 126, no. 1, pp. 12–22, 2016.

[35] S. Tangvarasittichai, "Oxidative stress, insulin resistance, dyslipidemia and type 2 diabetes mellitus," *World Journal of Diabetes*, vol. 6, no. 3, pp. 456–480, 2015.

[36] K. Faeh, D. Vistisen, G. Pacini et al., "Insulin resistance is accompanied by increased fasting glucagon and delayed glucagon suppression in individuals with normal and impaired glucose regulation," *Diabetes*, vol. 65, no. 11, pp. 3473–3481, 2016.

[37] J. E. Hall, *Guyton and Hall Textbook of Medical Physiology e-Book*, Elsevier Health Sciences, 2015.

[38] V. V. Kiselev, S. Versteyhe, L. Gauguin, and P. de Meyts, "Harmonic oscillator model of the insulin and IGF1 receptors’ allosteric binding and activation," *Molecular Systems Biology*, vol. 5, no. 1, p. 243, 2009.

[39] K. D. Copps and M. F. White, "Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2," *Diabetologia*, vol. 55, no. 10, pp. 2565–2582, 2012.

[40] C. X. Ho, G. Sriram, and K. M. Dipple, "Insulin sensitivity predictions in individuals with obesity and type II diabetes mellitus using mathematical model of the insulin signal transduction pathway," *Molecular Genetics and Metabolism*, vol. 119, no. 3, pp. 288–292, 2016.

[41] B. M. Koeppen and B. A. Stanton, *Berne and Levy Physiology e-book*, Elsevier Health Sciences, 2017.

[42] H. Yaribeygi, S. L. Atkin, and A. Sahebkar, "A review of the molecular mechanisms of hyperglycemia-induced free radical generation leading to oxidative stress," *Journal of Cellular Physiology*, vol. 234, no. 2, pp. 1300–1312, 2019.

[43] K. Rehman and M. S. H. Akash, "Mechanism of generation of oxidative stress and pathophysiology of type 2 diabetes mellitus: how are they interlinked?" *Journal of Cellular Biochemistry*, vol. 118, no. 11, pp. 3577–3585, 2017.

[44] M. L. Mizgier, S. Rutti, M. Pinget, and K. Bouzakri, "Beta-cell function and survival are modulated differentially by type I or type II muscle through specific myokinases," *Diabetes*, vol. 67, Supplement 1, pp. 266–21LB, 2018.

[45] E. Seelig, B. Trinh, H. Hanssen et al., "Exercise and the dipeptidyl-peptidase IV inhibitor sitagliptin do not improve beta-cell function and glucose homeostasis in long-lasting type 1 diabetes—a randomised open-label study," *Endocrinology, Diabetes & Metabolism*, vol. 2, no. 3, article e00075, 2019.

[46] D. Porte and S. E. Kahn, "Beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms," *Diabetes*, vol. 50, Supplement 1, pp. S160–S163, 2001.

[47] M. G. White, J. A. Shaw, and R. Taylor, "Type 2 diabetes: the pathologic basis of reversible β-cell dysfunction," *Diabetes Care*, vol. 39, no. 11, pp. 2080–2088, 2016.

[48] G. Drews, P. Krippet-Drews, and M. Düfer, "Oxidative stress and beta-cell dysfunction," *Pflügers Archiv-European Journal of Physiology*, vol. 460, no. 4, pp. 703–718, 2010.

[49] J. F. Turrens, "Mitochondrial formation of reactive oxygen species," *The Journal of Physiology*, vol. 552, no. 2, pp. 335–344, 2003.

[50] P. Newsholme, D. Morgan, E. Rebelato et al., "Insights into the critical role of NADPH oxidase (s) in the normal and dysregulated pancreatic beta cell," *Diabetologia*, vol. 52, no. 12, pp. 2489–2498, 2009.

[51] Y. Uchizono, R. Takeya, M. Iwase et al., "Expression of isoforms of NADPH oxidase components in rat pancreatic islets," *Life Sciences*, vol. 80, no. 2, pp. 133–139, 2006.
Oxidative Medicine and Cellular Longevity

[52] G. Lenaz, “The mitochondrial production of reactive oxygen species: mechanisms and implications in human pathology,” *IUBMB Life*, vol. 52, no. 3-5, pp. 159–164, 2001.

[53] D. L. Eizirik, M. L. Colli, and F. Ortu, “The role of inflammation in insulinitis and β-cell loss in type 1 diabetes,” *Nature Reviews Endocrinology*, vol. 5, no. 4, pp. 219–226, 2009.

[54] A. A. Starkov, B. M. Polster, and G. Fiskum, “Regulation of hydrogen peroxide production by brain mitochondria by calcium and Bax,” *Journal of Neurochemistry*, vol. 83, no. 1, pp. 220–228, 2002.

[55] P. A. Gerber and G. A. Rutter, “Regulation of SH-group reagents on Ca2+ and K+ channel currents of pancreatic β-cells,” *Biochemical and Biophysical Research Communications*, vol. 200, no. 2, pp. 860–866, 1994.

[56] M. S. Islam, P.-O. Berggren, and O. Larsson, “Sulphhydryl oxidation induces rapid and reversible closure of the ATP-regulated K+ channel in the pancreatic β-cell,” *FEBS Letters*, vol. 319, no. 1-2, pp. 128–132, 1993.

[57] B. Gier, P. Krippeit-Drews, T. Sheiko et al., “Suppression of KATP channel activity protects murine pancreatic β-cells against oxidative stress,” *The Journal of Clinical Investigation*, vol. 119, no. 11, pp. 3743–3748, 2007.

[58] R. P. Robertson, “Pancreatic islet β-cell and oxidative stress: the importance of glutathione peroxidase,” *FEBS Letters*, vol. 581, no. 19, pp. 3743–3748, 2007.

[59] G. Drews, C. Krämer, M. Dufèr, and P. Krippeit-Drews, “Contrasting effects of alloxan on islets and single mouse pancreatic β-cells,” *Biochemical Journal*, vol. 352, no. 2, pp. 389–397, 2000.

[60] P. Krippeit-Drews, S. Britsch, F. Lang, and G. Drews, “Effects of SH-group reagents on Ca2+ and K+ channel currents of pancreatic β-cells,” *Biochemical and Biophysical Research Communications*, vol. 200, no. 2, pp. 860–866, 1994.

[61] S. Guo, C. Dai, M. Guo et al., “NADPH oxidase-dependent reactive oxygen species and hypoxia in pancreatic beta-cell dysfunction in diabetes mellitus,” *Antioxidants & Redox Signaling*, vol. 26, no. 10, pp. 501–518, 2017.

[62] P. Robertson and J. S. Harmon, “Pancreatic islet β-cell and oxidative stress: the importance of glutathione peroxidase,” *FEBS Letters*, vol. 581, no. 19, pp. 3743–3748, 2007.

[63] G. Drews, C. Krämer, M. Dufèr, and P. Krippeit-Drews, “Contrasting effects of alloxan on islets and single mouse pancreatic β-cells,” *Biochemical Journal*, vol. 352, no. 2, pp. 389–397, 2000.

[64] P. Krippeit-Drews, S. Britsch, F. Lang, and G. Drews, “Effects of SH-group reagents on Ca2+ and K+ channel currents of pancreatic β-cells,” *Biochemical and Biophysical Research Communications*, vol. 200, no. 2, pp. 860–866, 1994.

[65] M. S. Islam, P.-O. Berggren, and O. Larsson, “Sulphhydryl oxidation induces rapid and reversible closure of the ATP-regulated K+ channel in the pancreatic β-cell,” *FEBS Letters*, vol. 319, no. 1-2, pp. 128–132, 1993.

[66] R. P. Robertson, “Oxidative stress and impaired insulin secretion in type 2 diabetes,” *Current Opinion in Pharmacology*, vol. 6, no. 6, pp. 615–619, 2006.

[67] B. Kang, X. Wang, Q. Xu, Y. Wu, X. Si, and D. Jiang, “Effect of 3-nitropriopionic acid inducing oxidative stress and apoptosis of granulosa cells in geese,” *Bioscience Reports*, vol. 38, no. 5, article BSR20180274, 2018.

[68] S. Alarifi, Ali, S. Alkahtani, and M. S. Alessia, “Regulation of apoptosis through bcl-2/bax proteins expression and DNA damage by nano-sized gadolinium oxide,” *International Journal of Nanomedicine*, vol. 12, pp. 4541–4551, 2017.

[69] K. Eguchi, I. Manabe, Y. Oishi-Tanaka et al., “Saturated fatty acid and TLR signaling link β cell dysfunction and islet inflammation,” *Cell Metabolism*, vol. 15, no. 4, pp. 518–533, 2012.

[70] R. Gill, A. Tsung, and T. Billiar, “Linking oxidative stress to inflammation: toll-like receptors,” *Free Radical Biology & Medicine*, vol. 48, no. 9, pp. 1121–1132, 2010.

[71] J. Liang, S. Y. Wu, D. Zhang, L. Wang, K. K. Leung, and P. S. Leung, “NADPH oxidase-dependent reactive oxygen species stimulate β-cell regeneration through differentiation of endocrine progenitors in murine pancreas,” *Antioxidants & Redox Signaling*, vol. 24, no. 8, pp. 419–433, 2016.

[72] M. Heinis, M. T. Simon, K. Ilc et al., “Oxygen tension regulates pancreatic beta-cell differentiation through hypoxia-inducible factor 1alpha,” *Diabetes*, vol. 59, no. 3, pp. 662–669, 2010.

[73] V. Miceli, M. Pampalone, G. Frazziano et al., “Carnosine protects pancreatic beta cells and islets against oxidative stress damage,” *Molecular and Cellular Endocrinology*, vol. 474, pp. 105–118, 2018.

[74] S. Guo, C. Dai, M. Guo et al., “Inactivation of specific β cell transcription factors in type 2 diabetes,” *The Journal of Clinical Investigation*, vol. 123, no. 8, pp. 3305–3316, 2013.

[75] S. H. Chiov, S. J. Chen, Y. L. Chang et al., “MafA promotes the reprogramming of placenta-derived multipotent stem cells into pancreatic islet-like and insulin+ cells,” *Journal of Cellular and Molecular Medicine*, vol. 15, no. 3, pp. 612–624, 2011.

[76] S. E. Hussey, S. L. McGee, A. Garnham, G. K. McConnell, and M. Hargreaves, “Exercise increases skeletal muscle GLUT4 gene expression in patients with type 2 diabetes,” *Diabetes, Obesity and Metabolism*, vol. 14, no. 8, pp. 768–771, 2012.

[77] E. A. Richter and M. Hargreaves, “Exercise, GLUT4, and skeletal muscle glucose uptake,” *Physiological Reviews*, vol. 93, no. 3, pp. 993–1017, 2013.

[78] C. M. Reno, E. C. Puente, Z. Sheng et al., “Brain GLUT4 knockout mice have impaired glucose tolerance, decreased insulin sensitivity, and impaired hypoglycemic counterregulation,” *Diabetes*, vol. 66, no. 3, pp. 587–597, 2017.

[79] M. Gaster, P. Staehr, H. Beck-Nielsen, H. D. Schrøder, and A. Handberg, “GLUT4 is reduced in slow muscle fibers of type 2 diabetic patients: is insulin resistance in type 2 diabetes a slow, type 1 fiber disease?,” *Diabetes*, vol. 50, no. 6, pp. 1324–1329, 2001.

[80] D. J. O’Gorman, H. K. R. Karlsson, S. McQuaid et al., “Exercise training increases insulin-stimulated glucose disposal and GLUT4 (SLC2A4) protein content in patients with type 2 diabetes,” *Diabetologia*, vol. 49, no. 12, pp. 2983–2992, 2006.

[81] G. Boden, C. Homko, C. A. Barrero et al., “Excessive caloric intake acutely causes oxidative stress, GLUT4 carboxylation, and insulin resistance in healthy men,” *Science Translational Medicine*, vol. 7, no. 304, article 304re7, 2015.

[82] P. Manna, A. E. Achari, and S. K. Jain, “Vitamin D supplementation inhibits oxidative stress and upregulates SIRT1/AMPK/GLUT4 cascade in high glucose-treated 3T3L1 adipocytes and in adipose tissue of high fat diet-fed diabetic mice,” *Archives of Biochemistry and Biophysics*, vol. 615, pp. 22–34, 2017.

[83] D. Pessler, A. Rudich, and N. Bashan, “Oxidative stress impairs nuclear proteins binding to the insulin responsive element in the GLUT4 promoter,” *Diabetologia*, vol. 44, no. 12, pp. 2156–2164, 2001.

[84] D. J. Fazakerley, A. Y. Minard, J. R. Krycer et al., “Mitochondrial oxidative stress causes insulin resistance without disrupting oxidative phosphorylation,” *The Journal of Biological Chemistry*, vol. 293, no. 19, pp. 7315–7328, 2018.

[85] A. Rudich, A. Tirosh, R. Potashkin, R. Hemi, H. Kanety, and N. Bashan, “Prolonged oxidative stress impairs insulin-induced GLUT4 translocation in 3T3-L1 adipocytes,” *Diabetes*, vol. 47, no. 10, pp. 1562–1569, 1998.
[83] D. W. Cooke and M. D. Lane, “The transcription factor nuclear factor I mediates repression of the GLUT4 promoter by insulin,” The Journal of Biological Chemistry, vol. 274, no. 18, pp. 12917–12924, 1999.

[84] H. She and Z. Mao, “Regulation of myocyte enhancer factor-2 transcription factors by neurotoxins,” Neurotoxicology, vol. 32, no. 5, pp. 563–566, 2011.

[85] J. V. Esteves, F. J. Enguita, and U. F. Machado, “MicroRNAs-mediated regulation of skeletal muscle GLUT4 expression and translocation in insulin resistance,” Journal of Diabetes Research, vol. 2017, Article ID 7267910, 11 pages, 2017.

[86] J. He and B.-H. Jiang, “Interplay between reactive oxygen species and microRNAs in cancer,” Current Pharmacology Reports, vol. 2, no. 2, pp. 82–90, 2016.

[87] J. Matsuzaki and T. Ochiya, “Extracellular microRNAs and oxidative stress in liver injury: a systematic mini review,” Journal of Clinical Biochemistry and Nutrition, vol. 63, no. 1, pp. 6–11, 2018.

[88] Z. Wang, Y. Liu, N. Han et al., “Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer’s disease and correction by insulin,” Journal of Neuroscience Research, vol. 86, no. 15, pp. 3265–3274, 2008.

[89] R. Mackenzie and B. Elliott, “Akt/PKB activation and insulin signaling: a novel insulin signaling pathway in the treatment of type 2 diabetes,” Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, vol. 7, p. 55, 2014.

[90] M. J. Birnbaum, “Turning down insulin signaling,” The Journal of Clinical Investigation, vol. 108, no. 5, pp. 655–659, 2001.

[91] K. Paz, R. Hemi, D. LeRoith et al., “A molecular basis for insulin resistance. Elevated serine/threonine phosphorylation of IRS-1 and IRS-2 inhibits their binding to the juxtaembrane region of the insulin receptor and impairs their ability to undergo insulin-induced tyrosine phosphorylation,” The Journal of Biological Chemistry, vol. 272, no. 47, pp. 29911–29918, 1997.

[92] B. A. Maddux, W. See, Lawrence JC Jr, A. L. Goldfine, I. D. Goldfine, and J. L. Evans, "Protection against oxidative stress—induced insulin resistance in rat L6 muscle cells by micromolar concentrations of α-lipoic acid," Diabetes, vol. 50, no. 2, pp. 404–410, 2001.

[93] A. S. Blair, E. Hajduch, G. J. Litherland, and H. S. Hundal, “Regulation of glucose transport and glycogen synthesis in L6 muscle cells during oxidative stress evidence for cross-talk between the insulin and SAPK2/p38 mitogen-activated protein kinase signaling pathways,” The Journal of Biological Chemistry, vol. 274, no. 51, pp. 36293–36299, 1999.

[94] V. Aguirre, T. Uchida, L. Yenush, R. Davis, and M. F. White, “The c-Jun NH (2)-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser (307),” The Journal of Biological Chemistry, vol. 275, no. 12, pp. 9047–9054, 2000.

[95] J. W. Eriksson, “Metabolic stress in insulin’s target cells leads to ROS accumulation—a hypothetical common pathway causing insulin resistance,” FEBS Letters, vol. 581, no. 19, pp. 3734–3742, 2007.

[96] M. Balbbaa, S. A. Abdulmalek, and S. Khalil, “Oxidative stress and expression of insulin signaling proteins in the brain of diabetic rats: role of Nigella sativa oil and anti-diabetic drugs,” PLoS One, vol. 12, no. 5, article e0172429, 2017.

[97] M. Yuan, N. Konstantopoulos, J. Lee et al., “Reversal of Obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ,” Science, vol. 293, no. 5535, pp. 1673–1677, 2001.

[98] J. K. Kim, Y. J. Kim, J. J. Fillmore et al., “Prevention of fat-induced insulin resistance by salicylate,” The Journal of Clinical Investigation, vol. 108, no. 3, pp. 437–446, 2001.

[99] J. L. Rains and S. K. Jain, “Oxidative stress, insulin signaling, and diabetes,” Free Radical Biology & Medicine, vol. 50, no. 5, pp. 567–575, 2011.

[100] A. Bloch-Damti and N. Bashan, “Proposed mechanisms for the induction of insulin resistance by oxidative stress,” Antioxidants & Redox Signaling, vol. 7, no. 11-12, pp. 1553–1567, 2005.

[101] I. Talior, M. Yarkoni, N. Bashan, and H. Eldar-Finkelman, “Increased glucose uptake promotes oxidative stress and PKC-δ activation in adipocytes of obese, insulin-resistant mice,” American Journal of Physiology-Endocrinology And Metabolism, vol. 285, no. 2, pp. E295–E302, 2003.

[102] R. B. Goldberg, “Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications,” The Journal of Clinical Endocrinology & Metabolism, vol. 94, no. 9, pp. 3171–3182, 2009.

[103] H. Yaribeygi, N. Katsiki, A. E. Butler, and A. Sahebkar, “Effects of anti-diabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys,” Drug Discovery Today, vol. 24, no. 1, pp. 256–262, 2019.

[104] R. J. Perry, J. G. Camporez, R. Kursawe et al., “Hepatic acetyl CoA links adipose tissue inflammation to hepatic insulin resistance and type 2 diabetes,” Cell, vol. 160, no. 4, pp. 745–758, 2015.

[105] S. Sindhu, N. Akhter, H. Arefanian et al., “Increased circulating levels of fractalkine (CX3CL1) are associated with inflammatory chemokines and cytokines in individuals with type-2 diabetes,” Journal of Diabetes & Metabolic Disorders, vol. 16, no. 1, p. 15, 2017.

[106] S. Gupta, A. Maratha, J. Siedenienko et al., “Analysis of inflammatory cytokines and TLR expression levels in type 2 diabetes with complications,” Scientific Reports, vol. 7, no. 1, article 7633, 2017.

[107] C. B. Guest, M. J. Park, D. R. Johnson, and G. G. Freund, “The implication of proinflammatory cytokines in type 2 diabetes,” Frontiers in Bioscience, vol. 13, no. 1, pp. 5187–5194, 2008.

[108] S. Basu, A. Larsson, J. Vessby, B. Vessby, and C. Berne, “Type 1 diabetes is associated with increased cyclooxygenase-and cytokine-mediated inflammation,” Diabetes Care, vol. 28, no. 6, pp. 1371–1375, 2005.

[109] Y. Benomar, A. Gertler, P. de Lacy et al., “Central resistin overexpression induces insulin resistance through toll-like receptor 4,” Diabetes, vol. 62, no. 1, pp. 102–114, 2013.

[110] K. N. Keane, V. F. Cruzat, R. Carlessi, P. I. H. de Bittencourt, and P. Newsholme, “Molecular events linking oxidative stress and inflammation to insulin resistance and β-cell dysfunction,” Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 181643, 15 pages, 2015.
12

Oxidative Medicine and Cellular Longevity

[112] S. J. Richardson, A. Willcox, A. J. Bone, A. K. Foulis, and N. G. Morgan, "Islet-associated macrophages in type 2 diabetes," Diabetologia, vol. 52, no. 8, pp. 1686–1688, 2009.

[113] C. Nathan and A. Ding, "Nonresolving inflammation," Cell, vol. 140, no. 6, pp. 871–882, 2010.

[114] M. Krause, J. Rodrigues-Krause, C. O’Hagan et al., "Differential nitric oxide levels in the blood and skeletal muscle of type 2 diabetic subjects may be consequence of adiposity: a preliminary study," Metabolism, vol. 61, no. 11, pp. 1528–1537, 2012.

[115] H. Bae, C. H. Jeong, W. N. Cheng, K. Hong, H. G. Seo, and S. G. Han, "Oxidative stress-induced inflammatory responses and effects of N-acetylcysteine in bovine mammary alveolar cells," Journal of Dairy Research, vol. 84, no. 4, pp. 418–425, 2017.

[116] S. P. Weisberg, R. Leibel, and D. V. Tortoriello, "Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity," Endocrinology, vol. 149, no. 7, pp. 3549–3558, 2008.

[117] A. B. Goldfine, V. Fonseca, K. A. Jablonski et al., "The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial," Annals of Internal Medicine, vol. 152, no. 6, pp. 346–357, 2010.

[118] A. Fleischman, S. E. Shoelson, R. Bernier, and A. B. Goldfine, "Salsalate improves glycemia and inflammatory parameters in obese young adults," Diabetes Care, vol. 31, no. 2, pp. 289–294, 2008.

[119] C. M. Larsen, M. Faulenbach, A. Vaag, J. A. Ehres, M. Y. Donath, and T. Mandrup-Poulsen, "Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes," Diabetes Care, vol. 32, no. 9, pp. 1663–1668, 2009.

[120] A. B. Goldfine, V. Fonseca, K. A. Jablonski et al., "Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial," Annals of Internal Medicine, vol. 159, no. 1, pp. 1–12, 2013.

[121] T. H. Hauser, N. Salastekar, E. J. Schaefler et al., "Effect of targeting inflammation with salsalate: the TINSAL-CVD randomized clinical trial on progression of coronary plaque in overweight and obese patients using statins," JAMA Cardiology, vol. 1, no. 4, pp. 413–423, 2016.

[122] P. M. Ridker, B. M. Everett, A. Pradhan et al., "Low-dose methotrexate for the prevention of atherosclerotic events," The New England Journal of Medicine, vol. 380, no. 8, pp. 752–762, 2019.

[123] B. Zhang, Q. Shen, Y. Chen et al., "Myricitrin alleviates oxidative stress-induced inflammation and apoptosis and protects mice against diabetic cardiomyopathy," Scientific Reports, vol. 7, no. 1, article 44239, 2017.

[124] H. Ma, S. Y. Li, P. Xu et al., "Advanced glycation endproduct (AGE) accumulation and AGE receptor (RAGE) up-regulation contribute to the onset of diabetic cardiomyopathy," Journal of Cellular and Molecular Medicine, vol. 13, no. 9b, pp. 1751–1764, 2009.

[125] A. A. Elmarakby and J. C. Sullivan, "Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy," Cardiovascular Therapeutics, vol. 30, no. 1, pp. 49–59, 2012.

[126] R. S. Balaban, S. Nemoto, and T. Finkel, "Mitochondria, oxidants, and aging," Cell, vol. 120, no. 4, pp. 483–495, 2005.

[127] J. W. Elrod and A. B. Gustafsson, Editorial Overview: Mitochondria Biology, Elsevier, 2018.

[128] M. K. Montgomery and N. Turner, "Mitochondrial dysfunction and insulin resistance: an update," Endocrine Connections, vol. 4, no. 1, pp. R1–R15, 2015.

[129] S. Rose, R. E. Frye, J. Slattery et al., "Oxidative stress induces mitochondrial dysfunction in a subset of autistic lymphoblastoid cell lines," Translational Psychiatry, vol. 4, no. 4, article e377, 2014.

[130] J. Wada and A. Nakatsuka, "Mitochondrial dynamics and mitochondrial dysfunction in diabetes," Acta Medica Okayama, vol. 70, no. 3, pp. 151–158, 2016.

[131] S. Rose, R. E. Frye, J. Slattery et al., "Erratum: Oxidative stress induces mitochondrial dysfunction in a subset of autistic lymphoblastoid cell lines," Translational Psychiatry, vol. 5, no. 3, article e526, 2015.

[132] A. Agil, M. el-Hammadi, A. Jiménez-Aranda et al., "Melatonin reduces hepatic mitochondrial dysfunction in diabetic obese rats," Journal of Pineal Research, vol. 59, no. 1, pp. 70–79, 2015.

[133] M. D. Brand and D. G. Nicholls, "Assessing mitochondrial dysfunction in cells," Biochemical Journal, vol. 435, no. 2, pp. 297–312, 2011.

[134] V. L. Tokarz, P. E. MacDonald, and A. Klip, "The cell biology of systemic insulin function," The Journal of Cell Biology, vol. 217, no. 7, pp. 2273–2289, 2018.

[135] S. Supale, N. Li, T. Brun, and P. Maechler, "Mitochondrial dysfunction in pancreatic ß cells," Trends in Endocrinology & Metabolism, vol. 23, no. 9, pp. 477–487, 2012.

[136] S. Sifuentes-Franco, F. P. Pacheco-Moisés, A. D. Rodriguez-Carrizales, and A. G. Miranda-Díaz, "The role of oxidative stress, mitochondrial function, and apoptosis in diabetic polyneuropathy," Journal of Diabetes Research, vol. 2017, Article ID 1673081, 15 pages, 2017.

[137] I. Hininger-Favier, R. Benaraba, S. Coves, R. A. Anderson, and A. M. Roussel, "Green tea extract decreases oxidative stress and improves insulin sensitivity in an animal model of insulin resistance, the fructose-fed rat," Journal of the American College of Nutrition, vol. 28, no. 4, pp. 355–361, 2009.

[138] P. K. Bagul, H. Middela, S. Matapally et al., "Attenuation of insulin resistance, metabolic syndrome and hepatic oxidative stress by resveratrol in fructose-fed rats," Pharmacological Research, vol. 66, no. 3, pp. 260–268, 2012.

[139] N. Sahin, C. Orhan, F. Erten et al., "Effects of allyl isothiocyanate on insulin resistance, oxidative stress status, and transcription factors in high-fat diet/streptozotocin-induced type 2 diabetes mellitus in rats," Journal of Biochemical and Molecular Toxicology, vol. 33, no. 7, article e22328, 2019.

[140] S. A. Abdulmalek and M. Balbaa, "Synergistic effect of nanoselenium and metformin on type 2 diabetic rat model: diabetic complications alleviation through insulin sensitivity, oxidative mediators and inflammatory markers," PLoS One, vol. 14, no. 8, article e0220779, 2019.

[141] A. Udupa, P. S. Nahar, S. H. Shah, M. J. Kshirsagar, and B. B. Ghongane, "Study of comparative effects of antioxidants on insulin sensitivity in type 2 diabetes mellitus," Journal of Clinical and Diagnostic Research, vol. 6, no. 9, pp. 1469–1473, 2012.

[142] P. J. Manning, W. H. Sutherland, R. J. Walker et al., "Effect of high-dose vitamin E on insulin resistance and associated parameters in overweight subjects," Diabetes Care, vol. 27, no. 9, pp. 2166–2171, 2004.
[143] F. A. Ganjifrockwala, J. Joseph, and G. George, “Decreased total antioxidant levels and increased oxidative stress in South African type 2 diabetes mellitus patients,” *Journal of Endocrinology, Metabolism and Diabetes of South Africa*, vol. 22, no. 2, pp. 21–25, 2017.

[144] N. van der Schaft, J. D. Schoufour, J. Nano et al., “Dietary antioxidant capacity and risk of type 2 diabetes mellitus, pre-diabetes and insulin resistance: the Rotterdam study,” *European Journal of Epidemiology*, vol. 34, no. 9, pp. 853–861, 2019.

[145] I. C. West, “Radicals and oxidative stress in diabetes,” *Diabetic Medicine*, vol. 17, no. 3, pp. 171–180, 2000.

[146] A. Yashin, Y. Yashin, X. Xia, and B. Nemzer, “Antioxidant activity of spices and their impact on human health: a review,” *Antioxidants*, vol. 6, no. 3, p. 70, 2017.